** Shares of eye drug developer Alimera Sciences fall 16.67% to $4.61
** Co files lawsuit to compel ANI Pharmaceuticals to close merger transaction
** The lawsuit asks the court to require ANI to comply with its obligations to complete the transaction as contemplated by the agreement
** The companies announced their agreement in June, valuing ALIM at about $381 mln in upfront consideration
** ALIM up ~6% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。